Tania A. Thomas

Dr. Tania A. Thomas


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Pediatric Clinics of North America
Verified
Journal Article
Closed access
TTTania A. Thomas
Tania A. Thomas

21 March 2013 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
SHScott Heysell
Scott Heysell
TTTania A Thomas
Tania A Thomas
CSCosti D Sifri
Costi D Sifri
PRPatrice K Rehm
Patrice K Rehm
EHEric R Houpt
Eric R Houpt
F-fluorodeoxyglucose positron emission tomography (FDG-PET) is increasingly used to investigate for malignancy in the evaluation of pulmonary nodules, yet both active tuberculosis (TB) and malignancy have high uptake of FDG. Definitive diagnosis of TB can be further hindered in patients without growth of the organism from sputum.

30 May 2021 in Pulmonology
Verified
Journal Article
Open access
GMGiovanni Battista Migliori
Giovanni Battista Migliori
Dina ViscaDina Visca
Dina Visca
MBMartin van Den Boom
Martin van Den Boom
STSimon Tiberi
Simon Tiberi
DSDenise Rossato Silva
Denise Rossato Silva
CNcontributing members of the Global Tuberculosis Network
contributing members of the Global Tuberculosis Network
The scientific debate on the criteria guiding hospitalization of tuberculosis (TB) and COVID-19 patients is ongoing.

7 March 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JNJoanitah Nalunjogi
Joanitah Nalunjogi
SMSergio Mucching-Toscano
Sergio Mucching-Toscano
JSJean Pierre Sibomana
Jean Pierre Sibomana
RCRosella Centis
Rosella Centis
LDLia D'AMbrosio
Lia D'AMbrosio
GMGiovanni Battista Migliori
Giovanni Battista Migliori
Although evidence is growing on the overall impact of the COVID-19 pandemic on tuberculosis (TB) services, global studies based on national data are needed to better quantify the extent of the impact and the countries' preparedness to tackle the two diseases. The aim of this study was to compare the number of people with new diagnoses or recurrence of TB disease, the number of drug-resistant (DR)-TB, and the number of TB deaths in 2020 vs 2019 in 11 countries in Europe, Northern America, and Australia. TB managers or directors of national reference centers of the selected countries provided the agreed-upon variables through a validated questionnaire on a monthly basis. A descriptive analysis compared the incidence of TB and DR-TB and mortality of the pre-COVID-19 year (2019) vs the first year of the COVID-19 pandemic (2020). Comparing 2020 vs 2019, lower number of TB cases (new diagnosis or recurrence) was notified in all countries (except USA-Virginia and Australia), and fewer DR-TB notifications (apart from France, Portugal, and Spain). The deaths among TB cases were higher in 2020 compared to 2019 in most countries with three countries (France, The Netherlands, USA-Virginia) reporting minimal TB-related mortality. A comprehensive evaluation of medium-term impact of COVID-19 on TB services would benefit from similar studies in multiple settings and from global availability of treatment outcome data from TB/COVID-19 co-infected patients.

5 November 2018 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
MJMuseveni Justine
Museveni Justine
AYAnita Yeconia
Anita Yeconia
INIngi Nicodemu
Ingi Nicodemu
DADomitila Augustino
Domitila Augustino
JGJean Gratz
Jean Gratz
TTTania A Thomas
Tania A Thomas
Background: Dosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited. We evaluated plasma drug concentrations of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB) among children undergoing TB treatment in Tanzania when these dosing recommendations were being implemented.Methods: At the end of intensive-phase TB therapy, blood was obtained 2 hours after witnessed medication administration to estimate the peak drug concentration (C2h), measured using high-performance liquid chromatography or liquid chromatography–tandem mass spectrometry methods. Differences in median drug concentrations were compared on the basis of the weight-based dosing strategy using the Mann–Whitney U test. Risk factors for low drug concentrations were analyzed using multivariate regression analysis.Results: We enrolled 51 human immunodeficiency virus–negative children (median age, 5.3 years [range, 0.75–14 years]). The median C2hs were below the target range for each TB drug studied. Compared with children who received the “old” dosages, those who received the “revised” WHO dosages had a higher median C2h for RIF (P = .049) and PZA (P = .015) but not for INH (P = .624) or EMB (P = .143); however, these revised dosages did not result in the target range for RIF, INH, and EMB being achieved. A low starting dose was associated with a low C2h for RIF (P = .005) and PZA (P = .005). Malnutrition was associated with a low C2h for RIF (P = .001) and INH (P = .001).Conclusions: Among this cohort of human immunodeficiency virus–negative Tanzanian children, use of the revised dosing strategy for treating childhood TB did not result in the target drug concentration for RIF, INH, or EMB being reached.

30 April 2022 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
GMGiovanni Battista Migliori
Giovanni Battista Migliori
PTPei Min Thong2
Pei Min Thong2
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
Justin DenholmJustin Denholm
Justin Denholm
Marina TadoliniMarina Tadolini
Marina Tadolini
DSDenise Rossato Silva36
Denise Rossato Silva36
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions to family visits, and school closures) were collected from 24 countries spanning five continents. The majority of the countries implemented multiple lockdowns with partial or full reopening. There was an overall decrease in active tuberculosis, drug-resistant tuberculosis, and latent tuberculosis cases. Although national lockdowns were effective in containing COVID-19 cases, several indicators of tuberculosis were affected during the pandemic.